AbbVie Inc. (ABBV)

NYQ – Real Time Price. Currency in USD

247.69

-2.40 (-0.96%)

Market open: Aug 12, 2026, 1:00 PM EDT

249.90

-0.19 (-0.08%)

Previous after-hours: Aug 11, 2026, 7:59 PM EDT

11.08.2026

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie leverages a strong specialty drug portfolio to offset the loss of exclusivity for its former top-selling products. CVS Health continues to expand its integrated healthcare model through its massive insurance and pharmacy network.

11.08.2026

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

Skyrizi and Rinvoq drive ABBV's Q2 growth, with strong sales, market-share gains and new indications supporting the immunology franchise.

11.08.2026

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie has solid financials, tons of free cash flow, and it has tripled its dividend in the past decade. Pfizer's massive 6.4% yield may not be as risky as investors think, and the company has been investing in its future growth.

11.08.2026

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie has been willing to supplement its new drug pipeline through acquisitions. It plans to pay $10.6 billion to purchase clinical-stage biotech company Apogee Therapeutics.

10.08.2026

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

About a year ago, 24/7 Wall St. flagged four overlooked Dividend Aristocrats as stealth growth plays, arguing that boring income names carried real upside if the market ever noticed.

10.08.2026

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

AbbVie's growth rate was more than 10% this past quarter and has been rising in recent years. Its valuation may seem high, but acquisition-related expenses have weighed on its bottom line.

10.08.2026

3 Beaten-Down Healthcare Stocks to Buy in August

Year to date, the healthcare sector finds itself in the middle of the S&P 500's pack.

Videos

No Data

There is no data to display

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
ABBV	Erste Group	Buy	undefined >> undefined	August 5th 2026

Press releases

04.08.2026

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

If approved, BOTOX ® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle prominence and patient satisfaction with treatment IRVINE, Calif., Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults.

AbbVie Inc. (ABBV)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AbbVie Inc. (ABBV)

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

3 Beaten-Down Healthcare Stocks to Buy in August

Videos

No Data

Upgrades / Downgrades

Press releases

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

3 Beaten-Down Healthcare Stocks to Buy in August

Videos

No Data

Upgrades / Downgrades

Press releases

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Search stocks

AbbVie Inc. (ABBV)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

AbbVie Inc. (ABBV)

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

3 Beaten-Down Healthcare Stocks to Buy in August

Videos

No Data

Upgrades / Downgrades

Press releases

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

Is AbbVie Stock a Buy After Posting Strong Q2 Earnings?

3 Beaten-Down Healthcare Stocks to Buy in August

Videos

No Data

Upgrades / Downgrades

Press releases

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence